Loading…
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Mainstreaming Addiction Treatment Act of 2021
Client: AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS · Firm: AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS
Discussion with House and Senate offices on opioid addiction and the Mainstreaming Addiction Treatment Act of 2021 (H.R. 1384/S.445). Met with House and Senate to discuss issues related to drug pricing, drug shortages, and the drug supply chain. Met with White House to discuss issues related to drug pricing, drug shortages, and the drug supply chain. Discussed COVID-19 response recommendations, including pharmacist provision of testing and vaccination, with House offices, Senate offices, and agencies. Patient access to: pharmacist provided vaccinations COVID/flu/pediatric illnesses, COVID-19 testing, Emergency HIV prophylaxis, Initiation of oral antivirals for flu/COVID, Buprenorphine, Diabetes monitoring and management, Other pharmacist services authorized under state law.
Pharmacy and Medically Underserved Areas Enhancement Act
Client: AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS · Firm:
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS via AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS
2021 · third_quarter · Q3
Contact concerning FDA authority to manage drug shortages, regulation of pharmacy compounding, implementation of the Drug Quality and Security Act. Conversation with DEA regulation on Medication-Assisted Treatment and drug shortages. Discussed COVID-19 response recommendations with House and Senate Offices, White House Offices, and HHS and its subagencies, and DEA. Contact HHS, House and Senate Offices concerning rule enforcement of the 340B Drug Pricing Program. Contact FDA concerning the practice of White Bagging and Brown Bagging patient medications. Met with House and Senate offices to discuss the Protect 340B Act (H.R. 4390) and bills S.773 and H.R. 3203, also related to the 340B program.
Source: Senate LDA
Communicate with the Center for Medicare and Medicaid Services regarding Innovation Center, direct reimbursement under Medicare Program, annual payment updates, PBM transparency, pharmacy residency audit, and scope of practice. Discussion with House and Senate about increased prescription drug pricing, specifically on the Ensuring Innovation Act (S.415) and the Advancing Education on Biosimilars Act (s. 164). Communication on Direct and Indirect remuneration fees (DIR) under Medicare Part D and Medicare rebate reform. Communication with CMS and Congressional Offices on pharmacy residency programs audits. Communication with CMS, White House Offices, and Congressional Offices on Reimbursement through Medicare Part B. Discussed COVID-19 response recommendations, including pharmacist provision of testing and vaccination, with House and Senate Offices, and HHS. Discussed telehealth reimbursement and virtual supervision flexibilities for pharmacist services with CMS. Discussed continuation of PREP Act allowances with HHS. Discussion with House and Senate Offices about the Pharmacist and Medically Underserved Areas Enhancement Act (H.R. 2759/S. 1362)
To enable certain hospitals that were participating in or applied for the drug discount program under section 340B of the Public Health Service Act prior to the COVID-19 public health emergency to temporarily maintain eligibility for such program, and for other purposes.
Client: AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS · Firm: AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS
Contact concerning FDA authority to manage drug shortages, regulation of pharmacy compounding, implementation of the Drug Quality and Security Act. Conversation with DEA regulation on Medication-Assisted Treatment and drug shortages. Discussed COVID-19 response recommendations with House and Senate Offices, White House Offices, and HHS and its subagencies, and DEA. Contact HHS, House and Senate Offices concerning rule enforcement of the 340B Drug Pricing Program. Contact FDA concerning the practice of White Bagging and Brown Bagging patient medications. Met with House and Senate offices to discuss the Protect 340B Act (H.R. 4390) and bills S.773 and H.R. 3203, also related to the 340B program.
PROTECT 340B Act of 2021
Client: AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS · Firm: AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS
Contact concerning FDA authority to manage drug shortages, regulation of pharmacy compounding, implementation of the Drug Quality and Security Act. Conversation with DEA regulation on Medication-Assisted Treatment and drug shortages. Discussed COVID-19 response recommendations with House and Senate Offices, White House Offices, and HHS and its subagencies, and DEA. Contact HHS, House and Senate Offices concerning rule enforcement of the 340B Drug Pricing Program. Contact FDA concerning the practice of White Bagging and Brown Bagging patient medications. Met with House and Senate offices to discuss the Protect 340B Act (H.R. 4390) and bills S.773 and H.R. 3203, also related to the 340B program.
Pharmacy and Medically Underserved Areas Enhancement Act
Client: AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS · Firm: AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS
Communicate with the Center for Medicare and Medicaid Services regarding Innovation Center, direct reimbursement under Medicare Program, annual payment updates, PBM transparency, pharmacy residency audit, and scope of practice. Discussion with House and Senate about increased prescription drug pricing, specifically on the Ensuring Innovation Act (S.415) and the Advancing Education on Biosimilars Act (s. 164). Communication on Direct and Indirect remuneration fees (DIR) under Medicare Part D and Medicare rebate reform. Communication with CMS and Congressional Offices on pharmacy residency programs audits. Communication with CMS, White House Offices, and Congressional Offices on Reimbursement through Medicare Part B. Discussed COVID-19 response recommendations, including pharmacist provision of testing and vaccination, with House and Senate Offices, and HHS. Discussed telehealth reimbursement and virtual supervision flexibilities for pharmacist services with CMS. Discussed continuation of PREP Act allowances with HHS. Discussion with House and Senate Offices about the Pharmacist and Medically Underserved Areas Enhancement Act (H.R. 2759/S. 1362)
Advancing Education on Biosimilars Act of 2021
Client: AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS · Firm: AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS
Communicate with the Center for Medicare and Medicaid Services regarding Innovation Center, direct reimbursement under Medicare Program, annual payment updates, PBM transparency, pharmacy residency audit, and scope of practice. Discussion with House and Senate about increased prescription drug pricing, specifically on the Ensuring Innovation Act (S.415) and the Advancing Education on Biosimilars Act (s. 164). Communication on Direct and Indirect remuneration fees (DIR) under Medicare Part D and Medicare rebate reform. Communication with CMS and Congressional Offices on pharmacy residency programs audits. Communication with CMS, White House Offices, and Congressional Offices on Reimbursement through Medicare Part B. Discussed COVID-19 response recommendations, including pharmacist provision of testing and vaccination, with House and Senate Offices, and HHS. Discussed telehealth reimbursement and virtual supervision flexibilities for pharmacist services with CMS. Discussed continuation of PREP Act allowances with HHS. Discussion with House and Senate Offices about the Pharmacist and Medically Underserved Areas Enhancement Act (H.R. 2759/S. 1362)
A bill to amend the Federal Food, Drug, and Cosmetic Act with respect to the scope of new chemical exclusivity.
Client: AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS · Firm: AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS
Communicate with the Center for Medicare and Medicaid Services regarding Innovation Center, direct reimbursement under Medicare Program, annual payment updates, PBM transparency, pharmacy residency audit, and scope of practice. Discussion with House and Senate about increased prescription drug pricing, specifically on the Ensuring Innovation Act (S.415) and the Advancing Education on Biosimilars Act (s. 164). Communication on Direct and Indirect remuneration fees (DIR) under Medicare Part D and Medicare rebate reform. Communication with CMS and Congressional Offices on pharmacy residency programs audits. Communication with CMS, White House Offices, and Congressional Offices on Reimbursement through Medicare Part B. Discussed COVID-19 response recommendations, including pharmacist provision of testing and vaccination, with House and Senate Offices, and HHS. Discussed telehealth reimbursement and virtual supervision flexibilities for pharmacist services with CMS. Discussed continuation of PREP Act allowances with HHS. Discussion with House and Senate Offices about the Pharmacist and Medically Underserved Areas Enhancement Act (H.R. 2759/S. 1362)
Mainstreaming Addiction Treatment Act of 2021
Client: AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS · Firm: AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS
Discussion with House and Senate offices on opioid addiction and the Mainstreaming Addiction Treatment Act of 2021 (H.R. 1384/S.445). Met with House and Senate to discuss issues related to drug pricing, drug shortages, and the drug supply chain. Met with White House to discuss issues related to drug pricing, drug shortages, and the drug supply chain. Discussed COVID-19 response recommendations, including pharmacist provision of testing and vaccination, with House offices, Senate offices, and agencies. Patient access to: pharmacist provided vaccinations COVID/flu/pediatric illnesses, COVID-19 testing, Emergency HIV prophylaxis, Initiation of oral antivirals for flu/COVID, Buprenorphine, Diabetes monitoring and management, Other pharmacist services authorized under state law.
A bill to enable certain hospitals that were participating in or applied for the drug discount program under section 340B of the Public Health Service Act prior to the COVID-19 public health emergency to temporarily maintain eligibility for such program, and for other purposes.
Client: AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS · Firm: AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS
Contact concerning FDA authority to manage drug shortages, regulation of pharmacy compounding, implementation of the Drug Quality and Security Act. Conversation with DEA regulation on Medication-Assisted Treatment and drug shortages. Discussed COVID-19 response recommendations with House and Senate Offices, White House Offices, and HHS and its subagencies, and DEA. Contact HHS, House and Senate Offices concerning rule enforcement of the 340B Drug Pricing Program. Contact FDA concerning the practice of White Bagging and Brown Bagging patient medications. Met with House and Senate offices to discuss the Protect 340B Act (H.R. 4390) and bills S.773 and H.R. 3203, also related to the 340B program.
Communicate with the Center for Medicare and Medicaid Services regarding Innovation Center, direct reimbursement under Medicare Program, annual payment updates, PBM transparency, pharmacy residency audit, and scope of practice. Discussion with House and Senate about increased prescription drug pricing, specifically on the Ensuring Innovation Act (S.415) and the Advancing Education on Biosimilars Act (s. 164). Communication on Direct and Indirect remuneration fees (DIR) under Medicare Part D and Medicare rebate reform. Communication with CMS and Congressional Offices on pharmacy residency programs audits. Communication with CMS, White House Offices, and Congressional Offices on Reimbursement through Medicare Part B. Discussed COVID-19 response recommendations, including pharmacist provision of testing and vaccination, with House and Senate Offices, and HHS. Discussed telehealth reimbursement and virtual supervision flexibilities for pharmacist services with CMS. Discussed continuation of PREP Act allowances with HHS. Discussion with House and Senate Offices about the Pharmacist and Medically Underserved Areas Enhancement Act (H.R. 2759/S. 1362)
Discussion with House and Senate offices on opioid addiction and the Mainstreaming Addiction Treatment Act of 2021 (H.R. 1384/S.445). Met with House and Senate to discuss issues related to drug pricing, drug shortages, and the drug supply chain. Met with White House to discuss issues related to drug pricing, drug shortages, and the drug supply chain. Discussed COVID-19 response recommendations, including pharmacist provision of testing and vaccination, with House offices, Senate offices, and agencies. Patient access to: pharmacist provided vaccinations COVID/flu/pediatric illnesses, COVID-19 testing, Emergency HIV prophylaxis, Initiation of oral antivirals for flu/COVID, Buprenorphine, Diabetes monitoring and management, Other pharmacist services authorized under state law.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Drug Enforcement Administration (DEA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), SENATE, White House Office